Loading company…
Vita Therapeutics develops engineered cell therapies using induced pluripotent stem cells.
Founded in 2018 and based in Baltimore, Vita Therapeutics develops cell therapies using induced pluripotent stem cells for genetic disorders, including LGMD2A and FSHD. Its programs include patient-specific and allogeneic approaches. Douglas Falk and Peter Andersen co-founded the company, with Falk as CEO. In October 2022, it raised USD 30.89 mn in Series B funding, including investment from Cambrian Biopharma and Cedars-Sinai Health System.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in